| Home Market Dynamics Macro Trends Sector Trends Company Insights AI Investing Strategies Sign Up Login |
| The sector is witnessing significant advancements and consistent performance in healthcare stocks, driven by innovations in health technology and pharmaceuticals. Strong representation is noted in health insurance advancements and earnings discussions, with emerging opportunities further highlighted. Despite a positive landscape, rising healthcare costs and criticism related to profit margins present challenges for the industry. Reports of regulatory issues and legal controversies also contribute to the sector's complex outlook. The price action of Health Care (XLV) sector is shaped by numerous forces, ranging from broad macroeconomic trends to company-specific performance and market structure. The trend sentiment at -0.9 is bearish. The market sentiment at 0.9 is bullish. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next.There is no clear direction for XLV since trend sentiment and market sentiment are at the opposite directions. The positive sentiment force for Health Care sector is at 1.1, and the negative at -0.2 on 2026-04-28. The forces of Valuation Sentiment (1.5), Sentiment towards Fundamentals (1.3), Broad Market Trend (1.2), Market Risk Appetite (1), Price Level Sentiment (1), and Option Sentiment (0.3) will drive up the price. The forces of and Sector Price Trend (-0.9) will drive down the price. The sentiment for Broad Market Trend is calculated based on SPY trend. The sentiment for Sector Price Trend is calculated based on XLV trend. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Prefrence is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band. |
Sign up to reveice Sector Rotation Notification
| XLV | ||||||||||||||
| Date | Attention | Price | StdDev | Price Level | Change | 10 Day Trend | Trend Sentiment | Hourly Trend Sentiment | Hourly StdDev | Market Sentiment | Action | P | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-27 | 0%(1.4%) | 143.46 | 1.16% | -2 | -0.51% | -0.27% | -0.9 | -0.1 | 0.6% | 0.9 | Wait | 50% | 1.3 | -0.5 |
| 2026-04-26 | 5%(1.9%) | -0.9 | 0.5 | 1.1 | 2.5 | |||||||||
| 2026-04-25 | 1%(2%) | -0.9 | 0.5 | 0.9 | 6 | |||||||||
| 2026-04-24 | 0%(1.9%) | 144.19 | 1.17% | 10 | -1.39% | -0.2% | -0.9 | -0.1 | 0.7% | 0.7 | Short | 55% | 0.8 | 2.5 |
| 2026-04-23 | 2%(1.9%) | 146.22 | 1.08% | 38 | -0.08% | -0.2% | -0.3 | 0 | 0.3% | 1 | Long | 55% | 0.9 | 1.6 |
| 2026-04-22 | 1%(1.7%) | 146.34 | 1.08% | 40 | 0.29% | -0.27% | -0.4 | -0.1 | 0.4% | 1.3 | Short | 55% | 1.1 | 2.2 |
| 2026-04-21 | 1%(1.7%) | 145.92 | 1.12% | 35 | -1.02% | 0% | -0.3 | -0.3 | 0.7% | 0.8 | Short | 55% | 1 | 4.5 |
| 2026-04-20 | 3%(1.7%) | 147.43 | 1.15% | 59 | -0.9% | 0.07% | 0.1 | -0.2 | 0.5% | 1.3 | Short | 55% | 1.4 | 3.7 |
| 2026-04-19 | 6%(1.4%) | 0.4 | 1.4 | 1.7 | 5.6 | |||||||||
| 2026-04-18 | 0%(0.7%) | 0.4 | 1.4 | 1.8 | -0.5 | |||||||||
| Wait is the preferred trading strategy with 50% chance of being right. Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. | ||||||||||||||
| Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force. | ||||||||||||||
| Analysis | ||
| ● Health Care Sector Check-Up: What Analysts Are Saying Right Now Mon. Sep 29, 2025 | ||
| Market News | ||
| 1 (6) Lilly’s Foundayo Is Big, But This Hidden Stock Catalyst Could Be Bigger Eli Lilly’s Foundayo launch is drawing attention, but analysts say eloralintide and combination therapies could drive the next leg of growth. (https://www.barrons.com/) Mon. Apr 27, 2026 | ||
| 2 (1) Thermo Fisher To Sell Microbiology Business To Astorg Thermo Fisher Scientific Inc. (TMO), on Monday, announced that it has signed a definitive agreement to sell its microbiology business to Astorg. The transaction is approximately $1. (https://www.rttnews.com/) Mon. Apr 27, 2026 | ||
| 3 (-8) Supreme Court Grills Bayer Over Failure to Warn Consumers About Roundup Risks Bayer is facing thousands of lawsuits brought by consumers who claim its flagship weedkiller causes cancer. (https://www.wsj.com/) Mon. Apr 27, 2026 | ||
| 4 (7) Lilly’s Foundayo Is Big, But This Hidden Stock Catalyst Could Be Bigger Eli Lilly’s Foundayo launch is drawing attention, but analysts say eloralintide and combination therapies could drive the next leg of growth. (https://www.barrons.com/) Mon. Apr 27, 2026 | ||
| 5 (8) Bloom Energy Stock Jumps After The Bell: Here's Why Bloom Energy shares are rising in after hours Monday after Oracle announced it will use Bloom Energy fuel cells for Project Jupiter. (https://www.benzinga.com/) Mon. Apr 27, 2026 | ||
| 6 (-4) Bayer Gets Mixed Reception at Supreme Court on Roundup Suits (Bloomberg) -- The US Supreme Court gave Bayer AG a mixed reception on its bid to stop tens of thousands of lawsuits claiming its Roundup herbicide should have been labeled as a cancer risk.Most Read from BloombergSergey Brin Confronted Gavin Newsom — Then Launched a Political WarThe Billion-Barrel Hormuz Oil Shock Is About to Crash DemandOpenAI Breaks Free From Exclusive AI Pact With MicrosoftTrump Being ‘Humiliated’ in Iran Talks, German Leader SaysIran Offers Deal to US to Reopen Strait and D (https://finance.yahoo.com/) Mon. Apr 27, 2026 | ||
| 7 (8) Centene Corp. stock outperforms competitors on strong trading day Shares of Centene Corp. CNC rallied 4.02% to $43.50 Monday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.12% to 7,173.91 and the Dow Jones Industrial Average DJIA falling 0.13% to 49,167.79. This was the stock's third consecutive day of gains. (https://www.marketwatch.com/) Mon. Apr 27, 2026 | ||
| 8 (-4) Bayer gets mixed reception at Supreme Court on Roundup suits (Bloomberg) -- The US Supreme Court gave Bayer AG a mixed reception on its bid to stop tens of thousands of lawsuits claiming its Roundup herbicide should have been labeled as a cancer risk.Most Read from BloombergSergey Brin Confronted Gavin Newsom — Then Launched a Political WarThe Billion-Barrel Hormuz Oil Shock Is About to Crash DemandOpenAI Breaks Free From Exclusive AI Pact With MicrosoftIran Offers Deal to US to Reopen Strait and Delay Nuclear Talks, Axios SaysChina Blocks Meta’s $2 Billi (https://finance.yahoo.com/) Mon. Apr 27, 2026 | ||
| 9 (7) Lilly’s Foundayo Is Big, But This Hidden Stock Catalyst Could Be Bigger Eli Lilly’s Foundayo launch is drawing attention, but analysts say eloralintide and combination therapies could drive the next leg of growth. (https://www.barrons.com/) Mon. Apr 27, 2026 | ||
| 10 (6) Humana partners with Mark Cuban's Cost Plus Drugs on technology, distribution NEW YORK, April 27 (Reuters) - Humana announced on Monday it will launch a pharmacy partnership with Mark Cuban's Cost Plus Drugs, with the health conglomerate's CenterWell pharmacy unit serving as a distributor for the platform. CenterWell will begin using SwiftyRx, Cost Plus Drugs' digital platform, to process prescriptions. (https://finance.yahoo.com/) Mon. Apr 27, 2026 | ||
| 11 (6) Eli Lilly to buy Ajax Therapeutics for up to $2.3 billion in blood cancer bet Eli Lilly said on Monday it would buy privately held blood cancer treatment developer Ajax Therapeutics for up to $2.3 billion in cash. (https://www.cnbc.com/) Mon. Apr 27, 2026 | ||
About
Contact Us
Copyright ©2025 TheMarketUnfolds. All rights reserved. Denver, Colorado, USA